TradersLink
$MBRXJul 6, 2026, 8:33 AM ETAI processed

MBRX: Early positive unblinded efficacy trends reported from first 45 patients in MIRACLE Phase 2/3

AI Summary

Moleculin's CEO said preliminary unblinded efficacy trends from the first 45 patients in Part A of the pivotal Phase 2/3 MIRACLE trial of Annamycin (AnnAraC) in relapsed/refractory AML look positive and discussed commercial opportunity and market research. The company cautioned the interim n=45 dataset is small, unblinded and not statistically significant, is subject to further review and follow-up, and it will require additional financing with no commitments.

Positives

  • Preliminary unblinded efficacy trends were reported as positive across both Annamycin treatment arms in the first 45 patients (Part A) of the MIRACLE trial
  • MIRACLE is a pivotal adaptive Phase 2/3 randomized, double-blind, placebo-controlled trial (higher regulatory relevance if confirmed)
  • Annamycin is positioned to avoid multidrug resistance and reportedly lacks typical anthracycline cardiotoxicity (company-stated de-risking attributes)

Negatives

  • Interim results are from a small sample (n=45), unblinded and have not achieved statistical significance
  • Dataset is preliminary and subject to review and potential change as more patients and long-term follow-up are added
  • Company states it will require significant additional financing to continue trials and has no financing commitments